Cancer Clinical Trials Office
The Cancer Clinical Trials Office (CCTO) at Beth Israel Deaconess Medical Center supports clinical research in all cancer related programs. Each disease group participates in a combination of phase I through phase IV trials that investigate new uses of FDA approved drugs as well as novel investigational agents. As part of a full service hospital, this disease programs are able to provide cohesive, patient- focused and comprehensive care for cancer patients involved in clinical research studies.
The CCTO supports BIDMCs participation as a Main Institution in the Eastern Cooperative Oncology Group (ECOG) and as a member institution of the Dana Farber/Harvard Cancer Center (DF/HCC). In addition to ECOG trials the CCTO supports other cooperative group, industry-sponsored, and investigator-initiated trials opened at BIDMC.
The CCTO coordinates and submits to the Institutional Review Board new protocols, protocol annual Continuing Reviews, protocol and consent form amendments and treatment toxicity and efficacy information in compliance with local and federal regulations. Routine self and external audits are conducted to ensure protocol compliance and quality, patient safety, and to promote continued staff education.
Clinical Trials
BIDMC investigators studying cancer help “translate” their laboratory discoveries into clinical trials that eventually lead to improved treatments that benefit patients here and elsewhere. Clinical trials are research studies that evaluate new procedures or drugs, weighing their effectiveness against current, standard protocols.
Our acclaimed clinical research team offers patients novel treatment options through a number of clinical trials. Through these special research studies, patients can access new, potentially more effective treatment options before they become more widely available.
As a founding member of the Dana Farber/Harvard Cancer Center, BIDMC patients benefit from the largest cancer research consortium in the country, and access to a broad array of the most current clinical trials.
The BIDMC cancer clinical trials office coordinates some 140 clinical trials in connection with:
- Dana-Farber/Harvard Cancer Center (DF/HCC)
- Eastern Cooperative Oncology Group (ECOG)
- National Institutes of Health (NIH)
- National Cancer Institute’s Specialized Programs of Research Excellence (SPORE)
BIDMC, along with the DF/HCC, has been conducting pivotal trials that have led to FDA approval for therapies for metastatic renal cancer and melanoma. We are now exploring ways to combine these novel agents or add them to established treatment plans, and to improve the selection criteria for systemic therapy (drugs via mouth or bloodstream) in order to improve patient outcome.
Click the links below for more specific clinical trial information:
Clinical trials for melanoma available at Beth Isreal Deaconess Medical Center
Clinical Trials available at the Dana-Farber/Harvard Cancer Center (DF/HCC)
Clinical Trials available at National Cancer Institute
